标题
CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date
作者
关键词
-
出版物
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume -, Issue -, Pages 1-15
出版商
Informa UK Limited
发表日期
2019-04-27
DOI
10.1080/14712598.2019.1611778
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- B-cell Therapy for Multiple Sclerosis: Entering an era
- (2018) Ariele L. Greenfield et al. ANNALS OF NEUROLOGY
- New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies
- (2018) Saskia Meyer et al. BRITISH JOURNAL OF HAEMATOLOGY
- Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
- (2018) E. C. Tallantyre et al. JOURNAL OF NEUROLOGY
- Antibodies to watch in 2018
- (2018) Hélène Kaplon et al. mAbs
- Reassessing B cell contributions in multiple sclerosis
- (2018) Rui Li et al. NATURE IMMUNOLOGY
- Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis
- (2018) Amit Bar-Or et al. NEUROLOGY
- Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases
- (2018) Anza B. Memon et al. PLoS One
- Ocrelizumab: A Review in Multiple Sclerosis
- (2018) Yahiya Y. Syed CNS DRUGS
- Ocrelizumab: a B-cell depleting therapy for multiple sclerosis
- (2017) Dejan Jakimovski et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions
- (2017) Rohit Loomba et al. GASTROENTEROLOGY
- Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab
- (2017) Evangelos A.A. Christou et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Monitoring CD27 + memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study
- (2017) M. Cohen et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
- (2017) Nicky Dunn et al. Multiple Sclerosis Journal
- Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
- (2017) Jeffrey M. Gelfand et al. Neurotherapeutics
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
- (2017) Nicky Dunn et al. Multiple Sclerosis Journal
- Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
- (2017) David Baker et al. EBioMedicine
- Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
- (2016) Peter Alping et al. ANNALS OF NEUROLOGY
- Anti-CD20 monoclonal antibodies in multiple sclerosis
- (2016) Irene Moreno Torres et al. Expert Review of Neurotherapeutics
- Rituximab in multiple sclerosis
- (2016) Jonatan Salzer et al. NEUROLOGY
- Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins
- (2016) Simone M. Brändle et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-CD20 monoclonal antibodies in multiple sclerosis
- (2016) Irene Moreno Torres et al. Expert Review of Neurotherapeutics
- International Consensus Document (ICON): Common Variable Immunodeficiency Disorders
- (2016) Francisco A. Bonilla et al. Journal of Allergy and Clinical Immunology-In Practice
- Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants
- (2015) Kevin Blauth et al. ACTA NEUROPATHOLOGICA
- Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study
- (2015) A.-P. Trouvin et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Circulating Follicular Regulatory T Cells Are Defective in Multiple Sclerosis
- (2015) Tessa Dhaeze et al. JOURNAL OF IMMUNOLOGY
- Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis
- (2015) L. Mozessohn et al. JOURNAL OF VIRAL HEPATITIS
- Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients
- (2015) M Radaelli et al. Multiple Sclerosis Journal
- Structural and functional features of central nervous system lymphatic vessels
- (2015) Antoine Louveau et al. NATURE
- Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients
- (2015) M Radaelli et al. Multiple Sclerosis Journal
- Alemtuzumab: A Review of Its Use in Patients with Relapsing Multiple Sclerosis
- (2014) Karly P. Garnock-Jones DRUGS
- Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis
- (2014) P. V. Beum et al. JOURNAL OF IMMUNOLOGY
- To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis
- (2014) Lucas Schirmer et al. Multiple Sclerosis Journal
- Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study
- (2014) P. S. Sorensen et al. NEUROLOGY
- Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
- (2014) Paul Emery et al. PLoS One
- B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes
- (2014) J. N. H. Stern et al. Science Translational Medicine
- Adverse cardiac events to monoclonal antibodies used for cancer therapy
- (2014) Nicholas G Kounis et al. OncoImmunology
- The mechanism of anti-CD20–mediated B cell depletion revealed by intravital imaging
- (2013) Fabricio Montalvao et al. JOURNAL OF CLINICAL INVESTIGATION
- Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
- (2013) Christian Klein et al. mAbs
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
- (2012) Ronald F van Vollenhoven et al. ANNALS OF THE RHEUMATIC DISEASES
- Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis
- (2012) Rajneesh Srivastava et al. NEW ENGLAND JOURNAL OF MEDICINE
- Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics
- (2012) Inmaculada De La Torre et al. RHEUMATOLOGY
- Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years
- (2011) Su-Hyun Kim ARCHIVES OF NEUROLOGY
- Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
- (2011) David B. Clifford ARCHIVES OF NEUROLOGY
- Treatment of multiple sclerosis with Anti-CD20 antibodies
- (2011) Barbara Barun et al. CLINICAL IMMUNOLOGY
- Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia
- (2011) John L Reagan et al. Expert Review of Anticancer Therapy
- A case of coronary hypersensitivity (Kounis) syndrome associated with mid-ventricular ballooning pattern, intracoronary thrombosis and troponin elevation
- (2011) Tommaso Gori et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis
- (2011) Kathryn M. Brennan et al. JOURNAL OF NEUROIMMUNOLOGY
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
- (2011) Ludwig Kappos et al. LANCET
- A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis
- (2010) Roberta Magliozzi et al. ANNALS OF NEUROLOGY
- Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
- (2010) F. Morschhauser et al. ANNALS OF ONCOLOGY
- Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study
- (2010) Mikkel Østergaard et al. ARTHRITIS AND RHEUMATISM
- Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial
- (2010) R. T. Naismith et al. NEUROLOGY
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis
- (2009) R. M. Fleischmann ARTHRITIS AND RHEUMATISM
- CD20 deficiency in humans results in impaired T cell–independent antibody responses
- (2009) Taco W. Kuijpers et al. JOURNAL OF CLINICAL INVESTIGATION
- Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
- (2008) Amit Bar-Or et al. ANNALS OF NEUROLOGY
- Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody
- (2008) Wim K. Bleeker et al. BRITISH JOURNAL OF HAEMATOLOGY
- Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis
- (2008) Birgit Obermeier et al. NATURE MEDICINE
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started